United Therapeutics (NASDAQ:UTHR) CFO Sells $5,492,900.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $549.29, for a total transaction of $5,492,900.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $10,368,398.04. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

James Edgemond also recently made the following trade(s):

• On Monday, June 8th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $547.50, for a total transaction of $5,475,000.00.
• On Thursday, June 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $546.28, for a total transaction of $5,462,800.00.
• On Monday, June 1st, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $547.87, for a total transaction of $5,478,700.00.
• On Thursday, May 28th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $565.63, for a total transaction of $5,656,300.00.
• On Tuesday, May 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $572.94, for a total transaction of $5,729,400.00.
• On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $564.11, for a total transaction of $5,641,100.00.
• On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $567.31, for a total transaction of $5,673,100.00.
• On Thursday, May 14th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $574.47, for a total transaction of $5,744,700.00.
• On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $573.03, for a total transaction of $5,730,300.00.
• On Thursday, May 7th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $578.58, for a total transaction of $5,785,800.00.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $545.96 on Monday. The firm has a 50-day moving average of $566.75 and a two-hundred day moving average of $521.65. The stock has a market cap of $23.18 billion, a P/E ratio of 20.15, a PEG ratio of 1.78 and a beta of 0.57. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period in the previous year, the company earned $6.63 earnings per share. As a group, equities analysts expect that United Therapeutics Corporation will post 26.84 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on UTHR shares. Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a research note on Thursday, May 7th. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Cantor Fitzgerald upped their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Finally, Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $619.42.

Institutional Investors Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of UTHR. Wellington Management Group LLP raised its stake in United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares during the period. Darwin Global Management Ltd. acquired a new stake in shares of United Therapeutics in the third quarter valued at approximately $317,617,000. Norges Bank acquired a new stake in shares of United Therapeutics in the fourth quarter valued at approximately $293,418,000. Avoro Capital Advisors LLC increased its stake in shares of United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after purchasing an additional 383,838 shares during the period. Finally, Janus Henderson Group PLC boosted its holdings in shares of United Therapeutics by 75.1% in the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after acquiring an additional 341,383 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.